Latest Asx Listing News

Vulcan Energy Resources reported a strong financing quarter with €509 million raised, offsetting operating and investing cash outflows and leaving the company well-funded heading into 2026.

Hydrocarbon Dynamics Limited has entered voluntary suspension pending a major transaction announcement while continuing global trials of its Multi-Flow product. A new auditor appointment and board leadership change mark a period of strategic transition.

Peregrine Gold has identified a second large-scale, high-grade Channel Iron Deposit near Newman, Western Australia, while expanding its Rocklea Gold Project footprint and maintaining a strong cash position.

Metgasco has secured shareholder approval to sell its 25% interests in the Odin and Vali gas fields for $5.9 million, marking a strategic exit from its core assets amid declining production and ongoing liquidity challenges.

Estrella Resources has reported multiple high-grade manganese intersections at its Ira Miri project, including assays up to 58% manganese, and received regulatory approval for a 30,000-tonne bulk sample extraction. Concurrently, drilling at the Werumata limestone project has been completed with assay results pending.

Kaiser Reef Limited reported a robust December quarter with nearly 7,000 ounces of gold produced at Henty, a 29% increase in gold reserves, and a strengthened cash position of A$43.1 million.

Arcadia Minerals Limited has voluntarily suspended trading of its shares pending a significant announcement about a capital raising and earn-in deal at the Swanson Tantalum mine.

Recharge Metals Limited progresses uranium exploration in the USA and Canada while appointing a new director and maintaining disciplined capital management.

WAM Active Limited has announced a significant capital raising through a pro-rata entitlement offer and a placement, aiming to bolster its investment capacity without materially affecting company control.

OzAurum Resources has raised $4.1 million through a strategic placement to Forrestania Resources, which will become a significant shareholder and support development at the James Stage 1 Open Pit in Western Australia.

Opthea Limited has streamlined its operations with a NASDAQ delisting and completed a strategic review, positioning itself to advance the OPT-302 treatment for LAM with a robust cash position.

Percheron Therapeutics has reported encouraging safety and efficacy signals from its HMBD-002 phase I trial, and outlined an innovative modular phase II trial design targeting multiple cancers in 2026.